These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

763 related items for PubMed ID: 18760136

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial).
    Page RL, Connolly SJ, Crijns HJ, van Eickels M, Gaudin C, Torp-Pedersen C, Hohnloser SH, ATHENA Investigators.
    Am J Cardiol; 2011 Apr 01; 107(7):1019-22. PubMed ID: 21296333
    [Abstract] [Full Text] [Related]

  • 4. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH, ATHENA Investigators.
    Circulation; 2009 Sep 29; 120(13):1174-80. PubMed ID: 19752319
    [Abstract] [Full Text] [Related]

  • 5. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.
    Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH, EURIDIS and ADONIS Investigators.
    N Engl J Med; 2007 Sep 06; 357(10):987-99. PubMed ID: 17804843
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.
    Hohnloser SH, Connolly SJ, Crijns HJ, Page RL, Seiz W, Torp-Petersen C.
    J Cardiovasc Electrophysiol; 2008 Jan 06; 19(1):69-73. PubMed ID: 18031520
    [Abstract] [Full Text] [Related]

  • 7. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM, Verma A, Talajic M, Nattel S, Dorian P, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 Jan 06; 27(1):47-59. PubMed ID: 21329862
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of dronedarone: a review of randomized trials.
    Christiansen CB, Torp-Pedersen C, Køber L.
    Expert Opin Drug Saf; 2010 Jan 06; 9(1):189-99. PubMed ID: 20001756
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the DIONYSOS study.
    Pamukcu B, Lip GY.
    Expert Opin Pharmacother; 2010 Dec 06; 11(17):2775-8. PubMed ID: 21050033
    [Abstract] [Full Text] [Related]

  • 14. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study).
    Shelton RJ, Clark AL, Goode K, Rigby AS, Houghton T, Kaye GC, Cleland JG.
    Heart; 2009 Jun 06; 95(11):924-30. PubMed ID: 19282313
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
    Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM.
    J Cardiovasc Electrophysiol; 2010 Jun 01; 21(6):597-605. PubMed ID: 20384650
    [Abstract] [Full Text] [Related]

  • 17. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone. A randomized, placebo-controlled study.
    Cotter G, Blatt A, Kaluski E, Metzkor-Cotter E, Koren M, Litinski I, Simantov R, Moshkovitz Y, Zaidenstein R, Peleg E, Vered Z, Golik A.
    Eur Heart J; 1999 Dec 01; 20(24):1833-42. PubMed ID: 10581142
    [Abstract] [Full Text] [Related]

  • 18. A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission.
    Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD.
    J Cardiovasc Pharmacol Ther; 2010 Dec 01; 15(4 Suppl):24S-30S. PubMed ID: 21098416
    [Abstract] [Full Text] [Related]

  • 19. A randomized controlled trial of magnesium sulfate, in addition to usual care, for rate control in atrial fibrillation.
    Davey MJ, Teubner D.
    Ann Emerg Med; 2005 Apr 01; 45(4):347-53. PubMed ID: 15795711
    [Abstract] [Full Text] [Related]

  • 20. Dronedarone: an overview.
    Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
    Ann Med; 2012 Feb 01; 44(1):60-72. PubMed ID: 21745093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.